Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Diversity in trials and responses across groups
Richard reviews trial demographics, African‑American representation, and no clear response differences so far.
Play episode from 18:09
Transcript
